オスペミフェン

危険有害性情報のコード(GHS)

• 絵表示(GHS)

  

• 注意喚起語

  Warning

• 危険有害性情報

  H410：長期的影響により水生生物に非常に強い毒性

• 注意書き

  P273：環境への放出を避けること。

  P501：内容物/容器を．．．に廃棄すること。

オスペミフェン 価格

オスペミフェン 化学特性,用途語,生産方法

• 外観

  白色～ほとんど白色粉末～結晶

• 効能

  骨粗鬆症治療薬, 選択的エストロゲン受容体モジュレータ (SERM)

• 説明

  In February 2013, the US FDA approved ospemifene (also referred to as FC1271a), for the treatment ofmoderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy (VVA), due tomenopause. It is estimated that there are 150 million postmenopausal women worldwide with 40–70% suffering from VVA. Ospemifene is a selective estrogen receptor (ER) modulator (SERM) and the first nonhormonal, nonestrogen for the treatment of moderate to severe dyspareunia in women with menopausal VVA. It binds to ERα (IC₅₀～800 nM) and ERβ (IC₅₀～1600 nM) with tissue-specific estrogenic agonist/antagonist effects. Treatment with ospemifene increases the thickness of the vaginal tissue thereby decreasing fragility of the tissue and reducing potential for pain during sexual intercourse.

• 使用

  Treatment of vaginal atrophy, osteoporosis, and vasomotor symptoms.

• 定義

  ChEBI: An organochlorine compound that is a selective estrogen receptor modulator; used for treatment of dyspareunia.

• 臨床応用

  Ospemifene is a SERM that is currently in Phase II/III clinical trials for the treatment of postmenopausal osteoporosis and urogenital atrophy. It is a known metabolite of toremifene, a triphenylethylene derivative used to treat breast cancer.Ospemifene has been shown to have beneficial effects on the bone without significant estrogen-related side effects. The beneficial effect observed on bone stems from this agent's ability to increase osteoblast proliferation and, as a result, to enhance bone mineralization as well as bone formation. Unlike tamoxifen, ospemifene does not induce osteocyte apoptosis.

オスペミフェン 生産企業

Global(151)Suppliers

オスペミフェン スペクトルデータ(¹HNMR)

128607-22-7, オスペミフェン キーワード